Form 4: Intuitive Surgical Officer Sells Shares Under 10b5-1 Plan

Intuitive Surgical's SVP & Chief Mfg and Supply Chain Officer, Mark Brosius, sold 464 shares of common stock for $548.49 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Brosius, SVP & Chief Mfg and Supply Chain Officer at Intuitive Surgical Inc. (ISRG), sold 464 shares of common stock.
• The sale occurred on December 15, 2025, at a price of $548.49 per share.
• The transaction was executed under a Rule 10b5-1 trading plan, which is set to expire on February 14, 2027.
• Following this transaction, Mr. Brosius directly beneficially owns 131 shares of Intuitive Surgical common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale is under a pre-arranged 10b5-1 plan, which mitigates concerns about immediate negative sentiment, it still represents a reduction in insider ownership.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to recent company news, which can mitigate concerns about insider sentiment.

Negatives

• An officer of the company sold 464 shares of common stock, reducing their direct beneficial ownership to 131 shares. While under a 10b5-1 plan, it still represents a reduction in insider holdings.

Future Outlook

NA

Industry Context

This filing details a specific insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, which could be interpreted slightly negatively, but the 10b5-1 plan context suggests it is not a reaction to new, adverse information.

Next Steps

• The Rule 10b5-1 trading plan under which this transaction occurred is set to expire on February 14, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled sale of a relatively small number of shares by an officer under a 10b5-1 plan. Such transactions are generally not indicative of a significant change in company fundamentals or management's long-term outlook. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Intuitive Surgical, ISRG, Insider Trading, Form 4, Stock Sale, Mark Brosius, 10b5-1 Plan, Officer Transaction, Medical Devices, Robotic Surgery